Capecitabine for low-risk triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage I breast cancer (tumor 2 cm or smaller and no cancer in lymph nodes).
- After surgery, the tumor was confirmed as triple negative breast cancer (no HER2, ER, or PR).
- You meet one of these low-risk features: high immune cells in the tumor, a specific hormone receptor type with low growth rate, or age 70 or older.
- You have not had chemotherapy, radiation, or targeted therapy before surgery.
- Your cancer has not spread to other parts of the body (stage 4).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial checks how a blood test that looks for cancer DNA (ctDNA) changes during and after you take capecitabine after early triple-negative breast cancer. It aims to see whether these blood test results can help monitor the chance of the cancer coming back.
This trial studies whether a low-dose “metronomic” chemotherapy medicine (capecitabine) added to standard hormone therapy can reduce breast cancer coming back. It is for people with hormone-receptor–positive, HER2-negative breast cancer after surgery and chemo.
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
This trial tests whether adding a combination of two chemotherapy drugs (cisplatin and gemcitabine) is better than the usual single drug (capecitabine) after surgery for people with triple negative breast cancer who still have cancer cells left after chemotherapy before surgery. The goal is to see if the extra treatment helps prevent the cancer from coming back.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.